flecainide has been researched along with Cardiomyopathy, Hypertrophic in 4 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagino, M | 1 |
| Ota, C | 1 |
| Onoki, T | 1 |
| Iwasawa, S | 1 |
| Haruki, S | 1 |
| Minami, Y | 1 |
| Suzuki, A | 1 |
| Hagiwara, N | 1 |
| Campbell, RW | 1 |
1 review available for flecainide and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Is drug treatment of tachyarrhythmias a science or a lottery?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Flecainide; Humans; Propafenone; Tachycardia | 1990 |
1 trial available for flecainide and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
2 other studies available for flecainide and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Male infant with Noonan syndrome with
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Flecainide; Heart Failure; Humans; I | 2022 |
Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Dose-Respo | 2015 |